Opko Health Q2 top line up 33% on surge in reference lab unit

OPKO Health (NASDAQ:OPK) Q2 results:

Revenues: $301.2M (+33.0%); reference lab services: $251.0M (+40.6%); product sales: $29.3M (+2.1%).

Net income: $33.7M (+156.4%); EPS: $0.05 (+150.0%).

BioReference Labs unit processed ~2.2M COVID-19 molecular tests during the quarter.

https://seekingalpha.com/news/3598047-opko-health-q2-top-line-up-33-on-surge-in-reference-lab-unit